

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Axel Riedel *et al.*

Serial No.: 10/757,015

Filed: January 14, 2004

Customer No.: 28501



Examiner: Leslie A. Royds

Art Unit: 1614

Docket: 1/1443US

Confirmation No.: 3296

For: PHARMACEUTICAL COMBINATION FOR THE PREVENTION OR
TREATMENT OF CARDIOVASCULAR, CARDIOPULMONARY, PULMONARY,
OR RENAL DISEASES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY UNDER 37 C.F.R. § 1.116
IN RESPONSE TO NOVEMBER 27, 2006, FINAL OFFICE ACTION

Sir:

This Reply is filed in response to the Final Office Action dated November 27, 2006. In that Office Action, a three month shortened statutory period was set for response. Applicants hereby petition for the necessary extension of time under 37 C.F.R. § 1.136 and authorize that the fee due under 37 C.F.R. § 1.16 in connection with this Reply be charged to Deposit Account No. 02-2955. The extension of time fee is paid by the enclosed Fee Transmittal Form. Furthermore, if it is determined that any additional fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Reply, authorization is hereby given to charge such fees to Deposit Account No. 02-2955.

Remarks begin on page 2 of this paper.